Protagonist Therapeutics Inc logo

PTGX

Protagonist Therapeutics Inc

$10.05

Earnings Summary

Net Profits
$-41.04Mn

Highlights

Net Profits:

Protagonist Therapeutics Inc’s net profit fell -33.06% since last year same period to $-41.04Mn in the Q2 2022. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -96.07% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Protagonist Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.93
EPS Estimate Current Year
-0.93

Highlights

EPS Estimate Current Quarter:

Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.93 - a -47.62% fall from last quarter’s estimates.

EPS Estimate Current Year:

Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.93.

Key Ratios

Key ratios of the Protagonist Therapeutics Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.23
Return on Equity (ROE)
-0.42
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Protagonist Therapeutics Inc’s return on assets (ROA) stands at -0.23.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Protagonist Therapeutics Inc’s return on equity (ROE) stands at -0.42.

Dividend Per Share (DPS):

Protagonist Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.63
-0.43
31.75%

Company Information

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.

Organisation
Protagonist Therapeutics Inc
Employees
79
Industry
Health Technology